- Home
- MAN vs IMCR Comparison
MAN vs IMCR Comparison
Compare MAN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAN
- IMCR
- Stock Information
- Founded
- MAN 1948
- IMCR 2008
- Country
- MAN United States
- IMCR United Kingdom
- Employees
- MAN N/A
- IMCR N/A
- Industry
- MAN Professional Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAN Consumer Discretionary
- IMCR Health Care
- Exchange
- MAN Nasdaq
- IMCR Nasdaq
- Market Cap
- MAN 2.1B
- IMCR 1.7B
- IPO Year
- MAN 1988
- IMCR 2021
- Fundamental
- Price
- MAN $39.20
- IMCR $34.21
- Analyst Decision
- MAN Hold
- IMCR Buy
- Analyst Count
- MAN 5
- IMCR 9
- Target Price
- MAN $48.40
- IMCR $57.00
- AVG Volume (30 Days)
- MAN 1.3M
- IMCR 286.9K
- Earning Date
- MAN 10-16-2025
- IMCR 11-05-2025
- Dividend Yield
- MAN 5.76%
- IMCR N/A
- EPS Growth
- MAN N/A
- IMCR N/A
- EPS
- MAN N/A
- IMCR N/A
- Revenue
- MAN $17,539,500,000.00
- IMCR $356,145,000.00
- Revenue This Year
- MAN $0.74
- IMCR $29.67
- Revenue Next Year
- MAN $3.40
- IMCR $11.12
- P/E Ratio
- MAN N/A
- IMCR N/A
- Revenue Growth
- MAN N/A
- IMCR 26.78
- 52 Week Low
- MAN $36.96
- IMCR $23.15
- 52 Week High
- MAN $75.17
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- MAN 50.76
- IMCR 48.79
- Support Level
- MAN $37.52
- IMCR $33.90
- Resistance Level
- MAN $39.20
- IMCR $37.00
- Average True Range (ATR)
- MAN 1.22
- IMCR 1.54
- MACD
- MAN 0.21
- IMCR 0.04
- Stochastic Oscillator
- MAN 79.72
- IMCR 39.35
About MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.